SDGR

Schrodinger, Inc. (SDGR) 2024 Annual Report Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2024. Schrodinger, Inc. operates a differentiated, physics-based computational platform used for drug discovery and materials science. The company operates through two reportable segments: Software (licensing solutions to biopharmaceutical and industrial companies) and Drug Discovery (collaborative and proprietary programs). As of December 31, 2024, the company had 891 full-time employees.

Key Financial Metrics

Note: 2023 net income was significantly boosted by a $147.2 million gain on equity investments from the Takeda acquisition of Nimbus Lakshmi. 2024 had no such gain.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 4% year-over-year. While Software revenue grew 13% (driven by hosted software and contributions), Drug Discovery revenue fell 53% due to the timing of milestone achievements and the discontinuation of certain collaboration projects.
• Profitability Shift: The company returned to a net loss position in 2024 ($187.1 million) compared to a net income of $40.7 million in 2023. The 2023 income was largely non-recurring, driven by the $147.2 million distribution from Nimbus. Excluding this, the company's core operations remain loss-making.
• Operating Expenses: Total operating expenses increased 7% to $341.4 million. Research and Development (R&D) expenses rose 11% to $201.8 million, reflecting continued investment in proprietary drug discovery programs (SGR-1505, SGR-2921, SGR-3515).
• Customer Growth: Annual Contract Value (ACV) increased to $190.8 million in 2024 from $154.2 million in 2023. Customer retention for contracts with ACV ≥ $100,000 was 95%.

Guidance, Outlook, and Management Commentary

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($367.5 million as of Dec 31, 2024), combined with a $150.0 million upfront payment received from Novartis in January 2025, are sufficient to fund operations for at least the next 24 months.
• Novartis Collaboration: In November 2024, Schrodinger entered a major collaboration with Novartis. The company received a $150.0 million upfront payment in January 2025 and is eligible for up to $2.272 billion in total milestone payments. No revenue was recognized from this deal in 2024.
• Proprietary Pipeline:
  • SGR-1505 (MALT1 inhibitor): Phase 1 trial in B-cell malignancies ongoing; initial data expected Q2 2025.
  • SGR-2921 (CDC7 inhibitor): Phase 1 trial in AML ongoing; Fast Track designation received; initial data expected H2 2025.
  • SGR-3515 (Wee1/Myt1 inhibitor): Phase 1 trial in solid tumors initiated; initial data expected H2 2025.
• Risks: The company faces risks related to the uncertainty of clinical trial outcomes, the ability to achieve milestones in collaborations, and the need for additional capital if operating expenses exceed projections. The company has a history of significant operating losses and expects to incur losses over the next several years.

Key Facts for Investor Verification

• Novartis Deal Terms: Verify the specific milestones and royalty rates associated with the $2.272 billion potential upside from the Novartis collaboration.
• Cash Burn Rate: Monitor quarterly cash flow from operations to assess if the 24-month runway remains valid given the $187 million net loss in 2024.
• Drug Discovery Milestones: Track the progress of SGR-1505, SGR-2921, and SGR-3515 clinical trials, as future revenue recognition is heavily dependent on these events.
• Software ACV vs. Revenue: Analyze the conversion of the growing ACV ($190.8M) into recognized revenue, noting the shift toward hosted software which recognizes revenue ratably.
• Equity Investment Volatility: Review the fair value adjustments of remaining equity investments (e.g., Structure Therapeutics) which can cause significant volatility in non-operating income/loss.